BG
Bellevue Group AG
13F filer · CIK 0001674546Reported Aug 14, 2026
Net buyer this quarter
13F portfolio value$4.75BU.S. long equity reported on 13F
Positions14717 new · 24 closed
Net flow last quarter+$33MBuys minus sells
Top 10 positions weight42.9%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 2026147 positions | |||||
| $308M | 6.49% | 0.16% | +188.3% | Q1 2016 | |
| $287M | 6.05% | 0.23% | -15.1% | Q1 2016 | |
| $279M | 5.88% | 0.49% | -3.8% | Q4 2018 | |
| $273M | 5.74% | 0.17% | +84.5% | Q1 2016 | |
| $196M | 4.13% | 0.49% | -32.1% | Q4 2020 | |
| $158M | 3.32% | 2.71% | +226.9% | Q1 2026 | |
| $149M | 3.13% | 0.64% | +13787.0% | Q1 2018 | |
| $135M | 2.83% | 2.01% | -31.7% | Q2 2019 | |
| NNUVLNuvalent, Inc. | $130M | 2.74% | 33.66% | Not reported | Q4 2025 |
| $124M | 2.60% | 5.94% | +0.1% | Q2 2022 | |
| $116M | 2.44% | 2.83% | -20.6% | Q3 2020 | |
| $115M | 2.41% | 1.36% | +65.6% | Q2 2023 | |
| $102M | 2.15% | 0.44% | +8976.3% | Q1 2016 | |
| $101M | 2.13% | 0.07% | -11.1% | Q1 2016 | |
| $98.1M | 2.06% | 0.17% | -43.6% | Q1 2016 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $98M | 2.06% | 2.48% | -20.1% | Q4 2025 |
| $88.6M | 1.86% | 0.61% | +4587.3% | Q1 2023 | |
| $88.5M | 1.86% | 5.42% | -0.3% | Q3 2023 | |
| $85.9M | 1.81% | 0.05% | -17.8% | Q1 2016 | |
| $84.5M | 1.78% | 0.07% | +23.6% | Q1 2016 | |
| $77.8M | 1.64% | 0.08% | +3.9% | Q1 2016 | |
| $77.1M | 1.62% | 0.59% | -46.5% | Q1 2016 | |
| $75.6M | 1.59% | 2.03% | -35.8% | Q1 2026 | |
| $73.4M | 1.54% | 2.38% | 0.0% | Q4 2025 | |
| $67.9M | 1.43% | 4.81% | -12.7% | Q4 2025 | |
| $66.9M | 1.41% | 0.13% | -11.9% | Q1 2016 | |
| $66.2M | 1.39% | 2.01% | -16.7% | Q1 2016 | |
| $62M | 1.30% | 0.02% | +0.6% | Q1 2016 | |
| $55.4M | 1.17% | 0.22% | +4.3% | Q1 2016 | |
| $44.7M | 0.94% | 1.53% | Not reported | Q1 2016 | |
| $44.4M | 0.94% | 3.05% | New | Q2 2026 | |
| $42.1M | 0.89% | 2.62% | -29.6% | Q1 2026 | |
| $41M | 0.86% | 1.46% | +21.9% | Q1 2026 | |
| $40M | 0.84% | 0.02% | +23.9% | Q1 2016 | |
| $37.9M | 0.80% | 0.06% | -39.5% | Q1 2016 | |
| $35.8M | 0.75% | 0.00% | -11.9% | Q1 2016 | |
| $35.1M | 0.74% | 0.56% | Not reported | Q4 2025 | |
| $32.5M | 0.68% | 0.08% | -30.7% | Q2 2018 | |
| $28.9M | 0.61% | 0.10% | -7.0% | Q1 2016 | |
| $28.8M | 0.61% | 0.26% | -83.9% | Q4 2021 | |
| $28.8M | 0.61% | 1.40% | -4.8% | Q1 2026 | |
| $27.4M | 0.58% | 0.02% | -28.9% | Q4 2016 | |
| $26.2M | 0.55% | 0.00% | -13.3% | Q1 2016 | |
| $23.9M | 0.50% | 2.05% | New | Q2 2026 | |
| $23.7M | 0.50% | 1.08% | New | Q2 2026 | |
| $23.6M | 0.50% | 0.20% | Not reported | Q1 2017 | |
| $23.4M | 0.49% | 2.75% | -20.5% | Q1 2024 | |
| $23.2M | 0.49% | 0.05% | -9.5% | Q1 2016 | |
| $21.8M | 0.46% | 0.03% | +7.5% | Q1 2016 | |
| $21.7M | 0.46% | 0.41% | -71.1% | Q4 2025 | |
| Q1 2026Reported May 15, 2026154 positions | |||||
| $304M | 7.25% | 0.27% | +0.1% | Q1 2016 | |
| $229M | 5.44% | 0.51% | -32.2% | Q4 2018 | |
| $215M | 5.12% | 0.30% | +1900.8% | Q1 2016 | |
| $176M | 4.19% | 3.01% | -11.6% | Q2 2019 | |
| $163M | 3.88% | 0.09% | +2117.7% | Q1 2016 | |
| $150M | 3.57% | 0.77% | -69.2% | Q4 2020 | |
| $137M | 3.25% | 1.10% | -62.1% | Q1 2016 | |
| $132M | 3.14% | 0.08% | -11.0% | Q1 2016 | |
| $132M | 3.13% | 6.56% | +54.3% | Q2 2022 | |
| $124M | 2.96% | 1.64% | +17.4% | Q4 2021 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $119M | 2.84% | 3.11% | +81088.1% | Q4 2025 |
| $118M | 2.81% | 0.07% | -12.6% | Q1 2016 | |
| NNUVLNuvalent, Inc. | $108M | 2.57% | 33.66% | +1.5% | Q4 2025 |
| $104M | 2.47% | 0.05% | +1497.5% | Q1 2016 | |
| $92M | 2.19% | 0.10% | -5.9% | Q1 2016 | |
| $91M | 2.17% | 3.81% | New | Q1 2026 | |
| $84.3M | 2.01% | 5.50% | Not reported | Q3 2023 | |
| $83M | 1.97% | 0.07% | +24.9% | Q1 2016 | |
| $77.6M | 1.85% | 0.18% | -47.4% | Q1 2016 | |
| $77.6M | 1.85% | 4.12% | -6.6% | Q3 2020 | |
| $71.4M | 1.70% | 0.06% | -39.8% | Q1 2016 | |
| $69.2M | 1.65% | 0.83% | Not reported | Q2 2023 | |
| $68.8M | 1.64% | 2.68% | +0.7% | Q4 2025 | |
| $67.2M | 1.60% | 0.15% | -19.5% | Q1 2016 | |
| $59.5M | 1.42% | 3.81% | New | Q1 2026 | |
| $50.2M | 1.19% | 1.66% | -38.9% | Q4 2025 | |
| $50.1M | 1.19% | 0.11% | -5.7% | Q2 2018 | |
| $49.9M | 1.19% | 2.42% | +92148.1% | Q1 2016 | |
| $49.5M | 1.18% | 0.20% | -6.9% | Q1 2016 | |
| $49.2M | 1.17% | 7.10% | +4.8% | Q4 2025 | |
| $48.1M | 1.15% | 1.42% | Not reported | Q2 2024 | |
| $40.1M | 0.95% | 0.02% | -15.4% | Q1 2016 | |
| $38.3M | 0.91% | 0.03% | +3.9% | Q4 2016 | |
| $38.1M | 0.91% | 1.80% | -66.8% | Q1 2016 | |
| $35.8M | 0.85% | 0.11% | -1.2% | Q1 2016 | |
| $34.3M | 0.82% | 0.23% | -12.3% | Q1 2016 | |
| $31.7M | 0.75% | 0.02% | -1.0% | Q1 2016 | |
| $31.2M | 0.74% | 0.00% | -0.2% | Q1 2016 | |
| $29.7M | 0.71% | 0.09% | -1.8% | Q3 2023 | |
| $29.4M | 0.70% | 1.20% | New | Q1 2026 | |
| $29.1M | 0.69% | 0.00% | -6.1% | Q1 2016 | |
| $28.6M | 0.68% | 3.45% | Not reported | Q1 2024 | |
| $26.2M | 0.62% | 0.04% | -10.7% | Q1 2016 | |
| $24.9M | 0.59% | 1.01% | New | Q1 2026 | |
| $24.9M | 0.59% | 0.01% | +124.3% | Q1 2016 | |
| $23.9M | 0.57% | 0.20% | -1.3% | Q1 2017 | |
| $22.1M | 0.53% | 0.10% | -1.8% | Q1 2024 | |
| $21.3M | 0.51% | 0.18% | -5.9% | Q1 2016 | |
| $20.6M | 0.49% | 1.48% | New | Q1 2026 | |
| $20.3M | 0.48% | 0.01% | -30.6% | Q1 2016 | |
| Q4 2025Reported Feb 17, 2026174 positions | |||||
| $399M | 7.56% | 2.54% | -10.2% | Q4 2020 | |
| $388M | 7.36% | 0.75% | -15.5% | Q4 2018 | |
| $380M | 7.20% | 2.94% | -23.1% | Q1 2016 | |
| $309M | 5.85% | 0.27% | +34.7% | Q1 2016 | |
| $242M | 4.58% | 1.70% | -3.4% | Q1 2016 | |
| ABRNAMAvidity Biosciences, Inc. | $190M | 3.60% | 1.74% | +22.2% | Q3 2025 |
| $182M | 3.46% | 0.09% | -7.6% | Q1 2016 | |
| $179M | 3.39% | 3.74% | +25.0% | Q2 2019 | |
| $177M | 3.36% | 0.34% | -0.1% | Q1 2016 | |
| $165M | 3.13% | 0.08% | -10.9% | Q1 2016 | |
| ATFOLDAmicus Therapeutics, Inc. | $153M | 2.90% | 3.45% | Not reported | Q1 2019 |
| $149M | 2.82% | 0.11% | -6.0% | Q1 2016 | |
| $136M | 2.57% | 4.28% | Not reported | Q2 2022 | |
| $127M | 2.40% | 0.09% | -20.1% | Q1 2016 | |
| NNUVLNuvalent, Inc. | $104M | 1.98% | 33.15% | New | Q4 2025 |
| $101M | 1.92% | 1.41% | +31174.6% | Q4 2021 | |
| $98.3M | 1.86% | 5.44% | +1.7% | Q1 2016 | |
| $97.1M | 1.84% | 5.52% | Not reported | Q3 2023 | |
| $88.9M | 1.69% | 0.18% | +16.3% | Q1 2016 | |
| $86M | 1.63% | 2.66% | New | Q4 2025 | |
| $73.6M | 1.40% | 0.06% | +0.9% | Q1 2016 | |
| $70.6M | 1.34% | 4.80% | 0.0% | Q3 2020 | |
| $64M | 1.21% | 0.12% | +23.4% | Q2 2018 | |
| $57.8M | 1.10% | 0.02% | +3.0% | Q1 2016 | |
| $56.2M | 1.07% | 0.22% | +7.8% | Q1 2016 | |
| $53.1M | 1.01% | 0.27% | -11.9% | Q1 2016 | |
| $51.6M | 0.98% | 0.09% | -10.5% | Q1 2016 | |
| $51.6M | 0.98% | 6.77% | New | Q4 2025 | |
| $44.6M | 0.84% | 0.03% | +18.8% | Q4 2016 | |
| $42.1M | 0.80% | 0.35% | -7.8% | Q1 2016 | |
| $38.8M | 0.74% | 0.11% | -2.2% | Q1 2016 | |
| $37.9M | 0.72% | 1.44% | -44.9% | Q2 2024 | |
| $37.7M | 0.71% | 0.02% | -38.7% | Q1 2016 | |
| $36.8M | 0.70% | 1.80% | New | Q4 2025 | |
| $36.5M | 0.69% | 0.00% | -16.1% | Q1 2016 | |
| $34.8M | 0.66% | 0.09% | -8.3% | Q3 2023 | |
| $34.8M | 0.66% | 2.89% | New | Q4 2025 | |
| $30.8M | 0.58% | 0.01% | -21.1% | Q1 2016 | |
| $30.3M | 0.57% | 0.04% | -10.2% | Q1 2016 | |
| $29.6M | 0.56% | 0.46% | +368.4% | Q4 2016 | |
| $26.2M | 0.50% | 0.01% | +69.5% | Q1 2016 | |
| $25.9M | 0.49% | 3.45% | Not reported | Q1 2024 | |
| $25.8M | 0.49% | 0.10% | -13.9% | Q1 2024 | |
| $25.3M | 0.48% | 0.79% | -63.6% | Q2 2019 | |
| $24.4M | 0.46% | 0.03% | -33.7% | Q1 2016 | |
| $23.9M | 0.45% | 0.15% | -0.1% | Q1 2016 | |
| $22.9M | 0.43% | 0.20% | -19.6% | Q1 2016 | |
| $22.1M | 0.42% | 0.20% | -2.2% | Q1 2017 | |
| $21.5M | 0.41% | 0.12% | -2.7% | Q1 2016 | |
| $20.6M | 0.39% | 0.02% | -33.9% | Q1 2016 | |
| Q3 2025Reported Nov 14, 2025146 positions | |||||
| $409M | 8.49% | 3.88% | -20.5% | Q1 2016 | |
| $403M | 8.37% | 0.90% | -4.3% | Q4 2018 | |
| $260M | 5.41% | 2.94% | +21.7% | Q4 2020 | |
| $248M | 5.14% | 1.77% | -3.1% | Q1 2016 | |
| $204M | 4.23% | 0.34% | -34.0% | Q1 2016 | |
| $198M | 4.12% | 0.20% | +14.5% | Q1 2016 | |
| $198M | 4.11% | 0.09% | -5.5% | Q1 2016 | |
| $167M | 3.46% | 0.12% | -15.7% | Q1 2016 | |
| $162M | 3.37% | 0.11% | -6.0% | Q1 2016 | |
| $156M | 3.24% | 0.10% | -8.0% | Q1 2016 | |
| $149M | 3.10% | 6.37% | +3.5% | Q1 2016 | |
| $122M | 2.54% | 0.73% | -8.3% | Q1 2016 | |
| $121M | 2.51% | 3.27% | +10.1% | Q2 2019 | |
| ATAKROAkero Therapeutics, Inc. | $113M | 2.36% | 2.98% | +20.4% | Q3 2022 |
| $102M | 2.11% | 5.54% | +14.5% | Q3 2023 | |
| ABRNAMAvidity Biosciences, Inc. | $93.8M | 1.95% | 1.47% | New | Q3 2025 |
| $92M | 1.91% | 5.35% | +7.6% | Q1 2016 | |
| $72.4M | 1.50% | 0.06% | -17.5% | Q1 2016 | |
| $70.1M | 1.46% | 2.85% | Not reported | Q4 2020 | |
| $69.7M | 1.45% | 0.15% | +0.9% | Q1 2016 | |
| $65.5M | 1.36% | 0.30% | -3.2% | Q1 2016 | |
| $58.7M | 1.22% | 0.02% | +19.5% | Q1 2016 | |
| $55.6M | 1.15% | 0.10% | -6.3% | Q1 2016 | |
| $52.9M | 1.10% | 0.20% | -8.7% | Q1 2016 | |
| $51.5M | 1.07% | 0.03% | -6.5% | Q1 2016 | |
| $48.9M | 1.02% | 0.10% | +0.1% | Q2 2018 | |
| $45.1M | 0.94% | 0.11% | -0.6% | Q1 2016 | |
| $45M | 0.94% | 2.62% | Not reported | Q2 2024 | |
| $43.6M | 0.91% | 4.83% | +1.4% | Q3 2020 | |
| $42.1M | 0.87% | 2.65% | Not reported | Q4 2019 | |
| $39.6M | 0.82% | 0.01% | +7.0% | Q1 2016 | |
| $37.2M | 0.77% | 0.38% | -15.6% | Q1 2016 | |
| $35.3M | 0.73% | 0.05% | +10.6% | Q1 2016 | |
| $34.8M | 0.72% | 0.10% | -10.2% | Q3 2023 | |
| $33.9M | 0.70% | 0.05% | +27.9% | Q1 2016 | |
| $32.5M | 0.68% | 0.02% | +19.8% | Q4 2016 | |
| $30.9M | 0.64% | 0.00% | -1.0% | Q1 2016 | |
| $30M | 0.62% | 2.55% | Not reported | Q2 2019 | |
| $29.3M | 0.61% | 0.03% | -6.2% | Q1 2016 | |
| $29.2M | 0.61% | 0.12% | +7.5% | Q1 2024 | |
| $29M | 0.60% | 0.06% | -14.0% | Q2 2018 | |
| $28M | 0.58% | 0.03% | -33.8% | Q1 2016 | |
| $24.2M | 0.50% | 0.12% | -8.4% | Q1 2016 | |
| $20M | 0.42% | 0.15% | -17.9% | Q1 2016 | |
| $19.9M | 0.41% | 0.06% | +55.3% | Q1 2016 | |
| $18.7M | 0.39% | 0.24% | -1.7% | Q1 2016 | |
| $18.1M | 0.38% | 0.20% | -4.1% | Q1 2017 | |
| $17.4M | 0.36% | 0.18% | +22.9% | Q3 2016 | |
| HHOLXHologic Inc | $16.7M | 0.35% | 0.11% | Not reported | Q1 2016 |
| $16.7M | 0.35% | 15.68% | Not reported | Q1 2016 | |
Premium opens every quarter this fund has filed